David Sinclair

Continuum Biosciences, Inc. operates as a biotech company that focuses on diseases such as obesity, diabetes, and ageing. The company was founded in 2017 and is headquartered in Blacksburg, VA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Life Biosciences, Inc. engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.

EdenRoc Sciences LLC engages in the business of biotechnology. The company was founded in 2016 and is headquartered in Birmingham, MI.

Immetas Therapeutics, Inc. develops novel therapeutics that modulates the innate immune system to treat age-related cancers and inflammatory diseases. The company was founded by J. Gene Wang and David A. Sinclair in October 2018 and is headquartered in East Hanover, NJ.

Arc Bio LLC is an American company that is revolutionizing microbial detection by providing turnkey metagenomics solutions that combine a next-generation sequencing laboratory workflow with an automated bioinformatics pipeline. Arc Bio is based in an undisclosed location. The private company's Galileo™ platform empowers researchers and laboratorians to transition into the next era of infectious disease detection through an integrated set of easy-to-use, actionable genomics tools. The company aims to create a healthier world by delivering robust sample-to-report microbial profiling workflows combined with data-driven health intelligence software tools to enable a new standard of care for disease detection and monitoring. The company was founded by David Andrew Sinclair, Todd Dickinson, David Sinclair, and Carlos Bustamante. Todd Dickinson has been the CEO since incorporation.